Navigation Links
BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/9/2011

LYNBROOK, N.Y., Nov. 9, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Lazard Capital Markets 8th Annual Healthcare Conference at 8:30am EST on Wednesday, November 16, 2011 in New York, NY.  

The live webcast of this presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or at the link http://wsw.com/webcast/lz11/bstc/.  

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease which is currently in Phase 3 pivotal clinical trials, frozen shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):